Misonix (NASDAQ:MSON) Raised to C at TheStreet

Misonix (NASDAQ:MSON) was upgraded by investment analysts at TheStreet from a “d+” rating to a “c” rating in a research note issued to investors on Tuesday, TheStreetRatingsTable reports.

NASDAQ MSON opened at $19.04 on Tuesday. The company has a debt-to-equity ratio of 0.26, a current ratio of 3.13 and a quick ratio of 2.43. The stock has a market capitalization of $331.14 million, a PE ratio of -13.04 and a beta of 1.48. Misonix has a 1 year low of $9.06 and a 1 year high of $20.71. The business’s 50-day moving average is $18.80 and its 200 day moving average is $14.57.

Misonix (NASDAQ:MSON) last posted its earnings results on Thursday, February 4th. The medical equipment provider reported ($0.07) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.29) by $0.22. The company had revenue of $18.26 million for the quarter. Misonix had a negative return on equity of 16.94% and a negative net margin of 35.03%.

Several hedge funds and other institutional investors have recently bought and sold shares of MSON. Citigroup Inc. grew its stake in shares of Misonix by 303.1% in the fourth quarter. Citigroup Inc. now owns 2,330 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 1,752 shares during the last quarter. Rhumbline Advisers grew its stake in shares of Misonix by 12.6% in the fourth quarter. Rhumbline Advisers now owns 13,351 shares of the medical equipment provider’s stock worth $167,000 after purchasing an additional 1,495 shares during the last quarter. Schonfeld Strategic Advisors LLC bought a new stake in shares of Misonix in the third quarter worth about $214,000. JPMorgan Chase & Co. grew its stake in shares of Misonix by 281.6% in the fourth quarter. JPMorgan Chase & Co. now owns 17,094 shares of the medical equipment provider’s stock worth $214,000 after purchasing an additional 12,614 shares during the last quarter. Finally, Mesirow Financial Investment Management Inc. boosted its position in Misonix by 7.4% during the 4th quarter. Mesirow Financial Investment Management Inc. now owns 24,835 shares of the medical equipment provider’s stock valued at $310,000 after acquiring an additional 1,719 shares in the last quarter. 41.19% of the stock is currently owned by institutional investors.

About Misonix

Misonix, Inc, together with its subsidiaries, designs, develops, manufactures, and markets minimally invasive surgical ultrasonic medical devices in the United States and internationally. The company's products include BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting and sculpting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells.

Recommended Story: Dividend Kings

Receive News & Ratings for Misonix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Misonix and related companies with MarketBeat.com's FREE daily email newsletter.